Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 39Breast Neoplasms 32Triple Negative Breast Neoplasms 25Neoplasm Metastasis 18Neoplasms 15Lung Neoplasms 15Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Stomach Neoplasms 6Ovarian Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Head and Neck Neoplasms 5Gallbladder Neoplasms 5Fallopian Tube Neoplasms 5Adenocarcinoma 5Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Pancreatic Ductal 4Carcinoma 4Neoplasms by Site 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Brain Neoplasms 3Biliary Tract Neoplasms 3Vaccinia 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

pembrolizumab 1fludarabine 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × 130-nm albumin-bound paclitaxel × 1 year × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡